Skip to main content

Table 4 Viral nucleic acid negative-converting rate within 14 days and not negative rate at last assay in patients with or without Arbidol based on gender, age and maximum body temperature

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Male Without Arbidol (n = 39) With Arbidol (n = 58) p value OR (95% CI)
Time to PCR negative in respiratory specimens
 ≤ 14 days (%) 19 (48.7) 45 (77.6) 0.005* 0.27 (0.11, 0.66)
 > 14 days (%) 20 (51.3) 13 (22.4) 0.005*  
 Not negative (%) 9 (23.1) 2 (3.4) 0.006* 8.40 (1.70, 41.42)
Female Without Arbidol (n = 24) With Arbidol (n = 41) p value OR (95% CI)
≤ 14 days (%) 16 (66.7) 27 (65.9) 1  
> 14 days (%) 8 (33.3) 14 (34.1) 1  
Not negative (%) 0 (0.00) 3 (7.3) 0.55  
≤ 50 years Without Arbidol (n = 30) With Arbidol (n = 59) p value OR (95% CI)
≤ 14 days (%) 16 (53.3) 43 (72.9) 0.096  
> 14 days (%) 14 (46.7) 16 (27.1) 0.096  
Not negative (%) 4 (13.3) 3 (5.1) 0.22  
> 50 years Without Arbidol (n = 33) With Arbidol (n = 40) p value OR (95% CI)
≤ 14 days (%) 19 (57.6) 28 (70.0) 0.33  
> 14 days (%) 14 (42.4) 12 (30.3) 0.33  
Not negative (%) 5 (15.2) 2 (5.0) 0.23  
≤ 38.5 C Without Arbidol (n = 42) With Arbidol (n = 67) p value OR (95% CI)
 ≤ 14 days (%) 24 (57.1) 47 (70.1) 0.22  
 > 14 days (%) 18 (42.9) 20 (29.9) 0.22  
Not negative (%) 6 (14.3) 4 (6.0) 0.18  
> 38.5C Without Arbidol (n = 21) With Arbidol (n = 32) p value OR (95% CI)
≤ 14 days (%) 11 (52.4) 25 (78.1) 0.07  
> 14 days (%) 10 (47.6) 7 (21.9) 0.07  
Not negative (%) 3 (14.3) 1 (3.1) 0.29  
  1. *Statistically significant p vaues